Hospital Authority

ha.org.hk

The Hospital Authority is a statutory body established on 1 December 1990 under the Hospital Authority Ordinance to manage all public hospitals in Hong Kong. It is an independent organization which is accountable to the Government through the Secretary for Food and Health who is responsible for the formulation of health policies and monitoring the performance of the Authority.

Related News

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

news image

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More

MEDTECH

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

news image

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More

MEDICAL

PANCREATIC CANCER CELLS HARNESS NORMAL TISSUE TURNOVER TO BUILD PROTECTIVE BARRIERS

NYU Langone Health | April 05, 2022

news image

In the presence of pancreatic tumors, certain immune cells break down structural proteins into molecules that trigger the building of dense tissue, a known barrier to therapy, a new study finds. Led by researchers from NYU Grossman School of Medicine, the study revolves around the dense protein meshwork that supports organs and helps to rebuild damaged tissue. Collagen protein fibers, the major component of the mesh, are continually broken down and replaced to maintain tensi...

Read More

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

news image

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More
news image

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More
news image

MEDTECH

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More
news image

MEDICAL

PANCREATIC CANCER CELLS HARNESS NORMAL TISSUE TURNOVER TO BUILD PROTECTIVE BARRIERS

NYU Langone Health | April 05, 2022

In the presence of pancreatic tumors, certain immune cells break down structural proteins into molecules that trigger the building of dense tissue, a known barrier to therapy, a new study finds. Led by researchers from NYU Grossman School of Medicine, the study revolves around the dense protein meshwork that supports organs and helps to rebuild damaged tissue. Collagen protein fibers, the major component of the mesh, are continually broken down and replaced to maintain tensi...

Read More
news image

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More